CHICAGO – In what could change the standard of care for advanced multiple myeloma (MM) patients, providing more hope for an otherwise dire diagnosis, anti-CD38 monoclonal antibody daratumumab reduced the risk of cancer progression by 61 percent and doubled partial and complete response rates just by being added to Velcade (bortezomib, Takeda Oncology Co.) and dexamethasone in a pivotal phase III trial.
CHICAGO – Early data of a phase II trial, called MyPathway, suggest validity for a new approach of treating patients according to genetic alterations – as opposed to tumor types – outside of approved indications.
CHICAGO – Representing the first biosimilar to demonstrate equivalency to blockbuster breast cancer drug Herceptin (trastuzumab) in a phase III trial, MYL-14010 hit the mark on all fronts, showing similar response rates, comparable adverse events and low immunogenicity.
SUZHOU, China – Two common themes ran throughout the Chinabio Partnering Forum: an improving Chinese regulatory environment and an increasing number of innovators and multinational corporations looking for cross-border partnerships.
SUZHOU, China – Snapping smartphone pictures of pharmaceutical company slides, entrepreneurs listened intently last week in a packed audience attending 15-minute presentations of business development executives looking for innovative products, not only in the Asia-Pacific region, but globally.
SUZHOU, China – Snapping smartphone pictures of pharmaceutical company slides, entrepreneurs listened intently Thursday in a packed audience attending 15-minute presentations of business development executives looking for innovative products, not only in the Asia-Pacific region, but globally.
SUZHOU, China – Two common themes ran throughout the first full day of the Chinabio Partnering Forum: an improving Chinese regulatory environment and an increasing number of innovators and multinational corporations looking for cross-border partnerships.
SUZHOU, China – In just under two years, Shanghai-based start-up Zai Labs Inc. has attracted the interest of large multinational pharmaceutical companies looking for a research, development and commercialization partner to navigate China's regulatory challenges and reach its large and untapped market potential.
SUZHOU, China – In just under two years, Shanghai-based start-up Zai Labs Inc. has attracted the interest of large multinational pharmaceutical companies looking for a research, development and commercialization partner to navigate China's regulatory challenges and reach its large and untapped market potential.
Bannockburn, Ill.-based Baxalta Inc. is helping set the pace toward another active year for partnership and licensing transactions. Late last month the company completed its second deal, reporting it was hooking up with Precision Bioscience Inc. in a potential $1.7 billion, six-target cancer deal centered on its gene editing technology. Baxalta paid $105 million up front with the rest earmarked for milestone payments.
